Study | Inclusion criteria | Age | Percent male | Duration (weeks) | Treatment | Dosage (mg/day) | Patients per arm | Effect size (SD) | Response (%) | Dropouts (%) |
---|---|---|---|---|---|---|---|---|---|---|
Goldstein et al. [9] | DSM-IV, Age 18–65 HAM-D17 ≥ 15, CGI-S ≥ 4 | 42 | 0.34 | 8 | Duloxetine Placebo | 40–120 | 70 70 | -0.3(0.03) | 0.64 0.48 | 0.34 0.34 |
Detke et al. [10] | DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 | 42 | 0.33 | 9 | Duloxetine Placebo | 60 | 123 122 | -0.6(0.02) | 0.62 0.29 |  |
Detke et al. [12] | DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 | 41 | 0.31 | 9 | Duloxetine Placebo | 60 | 128 139 | -0.2(0.02) | 0.65 0.42 | 0.39 0.35 |
Detke et al. [13] | DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 | 45 43 | 0.26 0.25 | 8 | Duloxetine Duloxetine Placebo | 80 120 | 95 93 93 | -0.3(0.02) -0.6(0.02) | 0.65 0.71 0.44 | 0.13 0.10 0.19 |
Goldstein et al. [14] | DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 | 41 41 | 0.4 0.38 | 8 | Duloxetine Duloxetine Placebo | 40 80 | 86 91 89 | -0.4(0.02) -0.5(0.02) | 0.54 0.60 0.30 | 0.36 0.42 0.42 |
Greist et al. [4] Falissard et al. [3] | DSM-IV, Age ≥ 18 |  |  | 8 | Duloxetine Placebo | 120 | 82 75 | -0.1(0.03) |  |  |
Greist et al. [4] Falissard et al. [3] | DSM-IV, Age ≥ 18 |  |  | 8 | Duloxetine Duloxetine Placebo | 40 80 | 91 84 90 | -0.2(0.02) -0.4(0.02) |  |  |
Greist et al. [4] Falissard et al. [3] | DSM-IV, Age ≥ 18 |  |  | 8 | Duloxetine Duloxetine Placebo | 80 120 | 93 103 99 | -0.3(0.02) -0.3(0.02) |  |  |
Brannan et al. [5] | DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 | 41 | 0.35 | 9 | Duloxetine Placebo | 60 | 141 141 | -0.2(0.02) | 0.42 0.40 | 0.16 0.09 |
Globally |  | 42 (1) | 0.33 | 8 (0.4) | Duloxetine Placebo | 20–120 | 1280 918 | -0.29(0.05) | 0.58(0.09) ** | -0.02(0.16) ** |